British Pharmacopoeia 2005

The British Pharmacopoeia has provided official standards for the quality of substances, medicinal products and articles used in medicine since its first publication in 1864. It is used in over 100 countries and remains an essential global reference in pharmaceutical research and development and quality control. This book explores how these standards have been achieved through a comprehensive review of the history and development of the pharmacopoeias in the UK, from the early London, Edinburgh and Dublin national pharmacopoeias to the creation of the British Pharmacopoeia and its evolution over 150 years. Trade in medicinal substances and products has always been global, and the British Pharmacopoeia is placed in its global context as an instrument of the British Empire as it first sought to cover the needs of countries such as India and latterly as part of its role in international harmonisation of standards in Europe and elsewhere. The changing contents of the pharmacopoeias over this period reflect the changes in medical practice and the development of dosage forms from products dispensed by pharmacists to commercially manufactured products, from tinctures to the latest monoclonal antibody products. The book will be of equal value to historians of medicine and pharmacy as to practitioners of medicine, pharmacy and pharmaceutical analytical chemistry.

Microbiological matters continue to exercise considerable influence on product quality. In both the pharmaceutical and medical device industries, products of greater sophistication, along with evolving regulatory requirements, are elevating the challenges related to maintaining microbiological integrity. Updated to reflect technological and regulatory changes, the Guide to Microbiological Control in Pharmaceuticals and Medical Devices, Second Edition covers thoseprincipal aspects of microbiology that arerelevant to the preformulation, formulation, manufacturing, and license application stages involved with the production of pharmaceuticals and medical devices. In recognition of the diverse disciplines involved in pharmaceutical and medical device production, this work provides a brief introduction to microbiology geared towards the nonmicrobiologist. Covering good manufacturing practice in the control of contamination, the text explores quality control, the preservation of formulations, and principles of sterilization, including microbiological-specific considerations for biotechnological products and other medical devices. It also provides additional materials on package integrity and contamination risks in clean rooms. The editors have produced a companion text, the Handbook of Microbiological Quality Control in Pharmaceuticals and Medical Devices (see reverse), which when paired with the Guide offers a complete theoretical and practical treatment of microbiological control. This book provides a comprehensive distillation of information concerning methodology and regulations that would otherwise remain scattered throughout the literature. It allows scientists from many fields to address potential problems in advance and implement suitable strategies at the earliest stages of development.

This report is structured in five parts: national framework for traditional and complementary medicine (T&CM); product regulation; practices and practitioners; the challenges faced by countries; and, finally, the country profiles. Apart from the section on practices and practitioners, the report is consistent with the format of the report of the first global survey in order to provide a useful comparison. The section on practices and practitioners, which covers providers, education and health insurance, is a new section incorporated to reflect the emerging trends in T&CM and to gather new information regarding these topics at a national level. All new information received has been incorporated into individual country profiles and data graphs. The report captures the three phases of progress made by Member States; that is, before and after the first WHO Traditional Medicine Strategy (1999-2005), from the first global survey to the second global survey (2005-2012) and from the second survey to the most recent timeline (2012-2018).

" British Pharmacopoeia" is the authoritative collection of standards for UK medicines and is an essential reference for anyone involved in pharmaceutical R&D, manufacture, testing and regulation. Containing: British Pharmacopoeia monographs British Pharmacopoeia (Veterinary) monographs Test methods Infrared Reference Spectra Supplementary information European Pharmacopoeia text

Argues that doctors are deliberately misinformed by profit-seeking pharmaceutical companies that casually withhold information about drug efficacy and side effects, explaining the process of pharmaceutical data manipulation and its global consequences. By the best-selling author of Bad Science.

The hard copy edition package contains a boxed five volume set with a separate Veterinary volume, a CD-ROM and access to a comprehensible, regularly updated website. Both the CD-ROM and online formats have networkable capacity. In more detail this set comprises: i) four volumes detailing all current UK pharmacopoeial standards for medicines for human use; ii) a companion volume providing standards for substances, preparations and immunological products used in veterinary medicine; and iii) a fully searchable CD-ROM which contains the contents of these volumes in electronic form together with a user manual, as well as the British Approved Names 2002 and supplements; iv) British pharmacopoeia chemical reference substances catalogue 2006-2007. The Pharmacopoeia is published on the recommendation of the Medicines Commission in accordance with the Medicines Act 1968. This edition is effective from 1 January 2007 and it incorporates the requirements of the 5th edition of the European Pharmacopoeia 2004 and its supplements. The British Pharmacopoeia (BP) 2007 is the authoritative, current collection of standards for UK medicinal substances and the official source of all UK quality standards. It is an essential reference for anyone involved in pharmaceutical Research & Development, manufacturing and testing, and plays a vital role in ensuring that all medicinal substances on the UK market meet standards of safety, quality and efficacy. The key features of this new edition are: extensive revisions including 30 new BP texts; new supplementary chapters containing general guidance on unlicensed medicines and method validation; the first BP monograph for traditional Chinese medicines; all European Pharmacopoeia 5th edition material up to and including Supplement 5.5 integrated into the text of BP 2007; value-for-money networking with full technical support from the publishers; CD-ROM and website deliver the complete text of the British

Pharmacopoeia, British Approved Names and European Pharmacopoeia standards directly to your PC: www.pharmacopoeia.co.uk is regularly updated and includes information on monograph development and contact points.
Although capillary electrophoresis (CE) technology has evolved quickly from the research laboratory into practical application in numerous fields, many scientists still debate its merits. While the body of international CE literature continues to expand dramatically, experts still question whether it has provided the speed, resolving power, peak capacity, sensitivity, robustness, and cost-reduction promised by its pioneers. Responding to these criticisms, this third edition brings together cutting-edge researchers to demonstrate the utility of CE across a broad spectrum of disciplines including— Forensic science Medical diagnostics Pharmaceutical science Genetic analysis Biotechnology Fluid mechanics Environmental science Biomedical research Nanotechnology Proteomics Detailed Analysis of New Methodologies and Applications Eagerly awaited by researchers and technicians who transformed the first two editions into bestsellers, this latest volume once again delivers. Emphasizing microseparations and microfluidics, the Handbook of Capillary and Microchip Electrophoresis, Third Edition features new chapters describing the use of microchip electrophoresis and associated microtechniques, with a focus on the extraordinary breadth of work undertaken to expand CE methodologies in recent years. Aided by contributions from leading international experts, this text remains a seminal reference for numerous chemistry, biology, and engineering fields.
Offering a valuable resource for medical and other historians, this book explores the processes by which pharmacy in Britain and its colonies separated from medicine and made the transition from trade to profession during the nineteenth and twentieth centuries. When the Pharmaceutical Society of Great Britain was founded in 1841, its founders considered pharmacy to be a branch of medicine. However, the 1852 Pharmacy Act made the exclusion of pharmacists from the medical profession inevitable, and in 1864 the General Medical Council decided that pharmacy legislation was best left to pharmacists themselves. Yet across the Empire, pharmacy struggled to establish itself as an autonomous profession, with doctors in many colonies reluctant to surrender control over pharmacy. In this book the author traces the professionalization of pharmacy by exploring issues including collective action by pharmacists, the role of the state, the passage of legislation, the extension of education, and its separation from medicine. The author considers the extent to which the British model of pharmacy shaped pharmacy in the Empire, exploring the situation in the Divisions of Empire where the 1914 British Pharmacopoeia applied: Canada, the West Indies, the Mediterranean colonies, the colonies in West and South Africa, India and the Eastern colonies, Australia, New Zealand, and the Western Pacific Islands. This insightful and wide-ranging book offers a unique history of British pharmaceutical policy and practice within the colonial world, and provides a firm foundation for further studies in this under-researched aspect of the history of medicine.
Used routinely in drug control laboratories, forensic laboratories, and as a research tool, thin layer chromatography (TLC) plays an important role in pharmaceutical drug analyses. It requires less complicated or expensive equipment than other techniques, and has the ability to be performed under field conditions. Filling the need for an up-to-date
Pharmacognosy (the science of biogenic or nature-derived pharmaceuticals and poisons) has been an established basic pharmaceutical science taught in institutions of pharmacy education for over two centuries. Over the past 20 years though it has become increasingly important given the explosion of new drugs, phytomedicines (plant medicines), nutraceuticals and dietary supplements – all of which need to be fully understood, tested and regulated. From a review of the previous edition: ‘Drawing on their wealth of experience and knowledge in this field, the authors, who are without doubt among the finest minds in pharmacognosy today, provide useful and fascinating insights into the history, botany, chemistry, phytotherapy and importance of medicinal plants in some of today’s healthcare systems. This is a landmark textbook, which carefully brings together relevant data from numerous sources and provides, in an authoritative and exhaustive manner, cutting-edge information that is relevant to pharmacists, pharmacognocists, complementary practitioners, doctors and nurses alike.’ The Pharmaceutical Journal ‘This is an excellent text book which provides fascinating insights into the world of pharmacognosy and the authors masterfully integrated elements of orthodox pharmacognosy and phytotherapy. Both the science student and the non-scientific person interested in phytotherapy will greatly benefit from reading this publication. It is comprehensive, easy to follow and after having read this book, one is so much more aware of the uniqueness of phytomedicines. A must read for any healthcare practitioner.’ Covers the history, biology and chemistry of plant-based medicines Covers pharmaceutical and neutraceuticals derived from plants Covers the role of medicinal plants in worldwide healthcare systems Examines the therapeutics and evidence of plant-based medicines by body system Sections on regulatory information expanded New evidence updates throughout New material covering non-medical supplements Therapeutics updated throughout Now on StudentConsult
Chinese Pharmacopoeia 2010 is an official and authoritative compendium of drugs. It covers most traditional Chinese medicines, most western medicines and preparations, giving information on the standards of purity, description, test, dosage, precaution, storage, and the strength for each drug. It is published in three volumes, and contains up to 4567 monographs with 1386 new admissions. In Volume I, it contains monographs of Chinese crude drugs and the prepared slices. Vegetable oil/fat and its extract, the patented Chinese traditional medicines, single ingredient of Chinese crude drug preparations etc. it has 2165 monographs with 1019 new admissions (439 articles of the prepared slice) and 634 revised; Volume II deals with monographs of chemical drugs, antibiotics, biochemical preparations, radiopharmaceuticals and excipients for pharmaceutical use, contains 2271 monographs with 330 new admissions and 1500 revised; Volume III contains biological products, has 131 monographs with 37 new admissions and 94 revised
Updated annually, the BP is the official, authoritative collection of standards for UK medicinal substances for human and veterinary use. The BP 2015 includes almost 3,500 monographs. All monographs and requirements of the European Pharmacopoeia are also reproduced in the BP, making it an essential reference for students, lecturers and researchers. The online product provides subscribers with access to the British pharmacopoeia 2019, British pharmacopoeia

(veterinary) 2019 and the current edition and supplements of Britsh approved names. Concurrent access to the 2014 onwards is also available

A collection of recommended procedures for analysis and specifications for the determination of pharmaceutical substances, excipients and dosage forms intended to serve as source material for reference by any WHO member state.

The second edition of the Encyclopedia of Toxicology continues its comprehensive survey of toxicology. This new edition continues to present entries devoted to key concepts and specific chemicals. There has been an increase in entries devoted to international organizations and well-known toxic-related incidents such as Love Canal and Chernobyl. Along with the traditional scientifically based entries, new articles focus on the societal implications of toxicological knowledge including environmental crimes, chemical and biological warfare in ancient times, and a history of the U.S. environmental movement. With more than 1150 entries, this second edition has been expanded in length, breadth and depth, and provides an extensive overview of the many facets of toxicology. Also available online via ScienceDirect – featuring extensive browsing, searching, and internal cross-referencing between articles in the work, plus dynamic linking to journal articles and abstract databases, making navigation flexible and easy. For more information, pricing options and availability visit www.info.sciencedirect.com. *Second edition has been expanded to 4 volumes *Encyclopedic A-Z arrangement of chemicals and all core areas of the science of toxicology *Covers related areas such as organizations, toxic accidents, historical and social issues, and laws *New topics covered include computational toxicology, cancer potency factors, chemical accidents, non-lethal chemical weapons, drugs of abuse, and consumer products and many more!

The genus Phyllanthus has over 1,000 species distributed worldwide, many of which have been used indigenously for the treatment of a variety of ailments for generations. Researchers have developed ways to analyze the potential of these plants and demonstrated the pharmacological action and various chemical entities present in each of them. They have validated the folklore claims and used this knowledge to design cost-effective and reliable sources of medicine. The first book to exclusively examine the genus Phyllanthus, Phyllanthus Species: Scientific Evaluation and Medicinal Applications begins with a systematic classification and identification manual for various plants in the genus, followed by the scientific evaluation of the species for modern medicinal use. This reference compiles cutting edge research from countries around the world, including the UK, Malaysia, India, Indonesia, Spain, Cuba, and China. Topics covered include phylogenetic analysis of Phyllanthus, chemistry of the genus, anti-cancer, anti-diabetic and chemo- protective effects, genotoxicity, clinical trials involving Phyllanthus, and various formulations containing different plants from the genus Phyllanthus. Phyllanthus Species: Scientific Evaluation and Medicinal Applications describes in detail the taxonomy, cultivation, and marketing, identification of geographic and genetic hot spots, chemistry, scientific evaluation, and clinical trials of various species of Phyllanthus. Written for researchers and educators in academia, industry, agriculture, and the interested general public, this book’s up-to-date references make it a powerful resource providing first-hand information on Phyllanthus.

This book continues as volume 7 of a multi-compendium on Edible Medicinal and Non-Medicinal Plants. It covers plant species with edible flowers from families Acanthaceae to Facaceae in a tabular form and seventy five selected species from Amaryllidaceae, Apocynaceae, Asclepiadaceae, Asparagaceae, Asteraceae, Balsaminaceae, Begoniaceae, Bignoniaceae, Brassicaceae, Cactaceae, Calophyllaceae, Caprifoliaceae, Caryophyllaceae, Combretaceae, Convolvulaceae, Costaceae, Doryanthaceae and Fabaceae in detail. This work will be of significant interest to scientists, medical practitioners, pharmacologists, ethnobotanists, horticulturists, food nutritionists, botanists, agriculturists, conservationists, lecturers, students and the general public. Topics covered include: taxonomy; common/English and vernacular names; origin and distribution; agroecology; edible plant parts and uses; botany; nutritive/pharmacological properties, medicinal uses, nonedible uses; and selected references.

Volumes in this widely revered series present comprehensive reviews of drug substances and additional materials, with critical review chapters that summarize information related to the characterization of drug substances and excipients. This organizational structure meets the needs of the pharmaceutical community and allows for the development of a timely vehicle for publishing review materials on this topic. The scope of the Profiles series encompasses review articles and database compilations that fall within one of the following six broad categories: Physical profiles of drug substances and excipients; Analytical profiles of drug substances and excipients; Drug metabolism and pharmacokinetic profiles of drug substances and excipients; Methodology related to the characterization of drug substances and excipients; Methods of chemical synthesis; and Reviews of the uses and applications for individual drug substances, classes of drug substances, or excipients. Presents comprehensive reviews covering all aspects of drug development and formulation of drugs Profiles creatine monohydrate and fexofenadine hydrochloride, as well as five others Meets the information needs of the drug development community

Nano- and Microscale Drug Delivery Systems: Design and Fabrication presents the developments that have taken place in recent years in the field of micro- and nanoscale drug delivery systems. Particular attention is assigned to the fabrication and design of drug delivery systems in order to i) reduce the side effects of therapeutic agents, ii) increase their pharmacological effect, and iii) improve aqueous solubility and chemical stability of different therapeutic agents. This book is designed to offer a cogent, concise overview of current scholarship in this important area of research through its focus on the characterization and fabrication of a variety of nanomaterials for drug delivery applications. It is an invaluable reference source for both biomaterials scientists and biomedical engineers who want to learn more about how nanomaterials are engineered and used in the design of drug delivery nanosystems. Shows how micro- and nanomaterials can be engineered to create more effective drug delivery systems Summarizes current nanotechnology research in the field of drug delivery systems Explores the pros and cons of using particular nanomaterials as therapeutic

agents Serves as a valuable reference for both biomaterials scientists and biomedical engineers who want to learn more about how nanomaterials are engineered and used in the design of drug delivery nanosystems

This volume is devoted to descriptions of non medical as well as medical uses for some drugs that have typically, or not so typically, been associated with drug abuse. One major objective of this book is to identify costs and benefits of drug abuse. The book highlights drugs including 3,4 methylenedioxymethamphetamine (MDMA), cannabinoids, opioids and methylphenidate because of their well-documented potential for abuse and provides new and emerging evidence of their potential to treat some chronic disease states alongside the potential consequences of exposure.

The British Pharmacopoeia (BP) 2016 will see the introduction of a new, integrated website pharmacopoeia.com that will provide a single place to access the BP online and to order British Pharmacopoeia Chemical Reference Substances. The site will replace pharmacopoeia.co.uk and will feature more information and a new look with improved functionality and accessibility. This edition also sees the introduction of a download format for use offline. This replaces the USB, and has the benefit of being updated three times per year to harmonise with the European Pharmacopoeia. Updated annually, the BP is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. The BP 2016 includes almost 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012, and becomes legally effective on 1 January 2016. Where a pharmacopoeial monograph exists, medicinal products sold or supplied in the UK must comply with the relevant monograph. All monographs and requirements of the European Pharmacopoeia are also reproduced in the BP.

Elektronisk udgave af the British Pharmacopoeia (BP). Der er licens til 1 enkelt bruger ad gangen med brug af login/password. Kun adgang fra én PC på Farmaceutisk Fakultetsbibliotek ved henvendelse i skranken.

Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes approximately 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012. Where a BP monograph exists, medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph.All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and beyond.

Winner of the James A. Duke Award for Excellence in Botanical Literature Award from the American Botanical CouncilCompiled by the American Herbal Pharmacopoeia, this volume addresses the lack of authoritative microscopic descriptions of those medicinal plant species currently in trade. It includes an atlas providing detailed text and graphic descri

This two-volume work presents comprehensive, accurate information on the present status and contemporary development in phycoremediation of various types of domestic and industrial wastewaters. The volume covers a mechanistic understanding of microalgae based treatment of wastewaters, including current challenges in the treatment of various organic and inorganic pollutants, and future opportunities of bioremediation of wastewater and industrial effluents on an algal platform. The editors compile the work of authors from around the globe, providing insight on key issues and state-of-the-art developments in algal bioremediation that is missing from the currently available body of literature. The volume hopes to serve as a much needed resource for professors, researchers and scientists interested in microalgae applications for wastewater treatment. Volume 1 focuses on the different aspects of domestic and industrial wastewater treatment by microalgae. The case studies include examples such as genetic technologies as well as the development and efficient use of designer consortia for enhanced utilization of microalgae. This volume provides thorough and comprehensive information on removal of persistent and highly toxic contaminants such as heavy metals, organic pesticides, polyaromatic hydrocarbons, endocrine disruptors, pharmaceutical compounds, and dyes from wastewater by microalgae, diatoms, and blue-green algae. Design considerations for algal ponds and efficient use of photobioreactors and HRAPs for wastewater treatment are some other highlights. This volume addresses the applications, potentials, and future opportunities for these various considerations in water pollution mitigation using algal technologies.

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

Completely revised and updated to reflect the significant advances in pharmaceutical production and regulatory expectations, this third edition of Validation of Pharmaceutical Processes examines and blueprints every step of the validation process needed to remain compliant and competitive. The many chapters added to the prior compilation examine va

This is thirty-fifth edition of Martindale, which provides reliable, and evaluated information on drugs and medicines used throughout the world. It contains encyclopaedic facts about drugs and medicines, with: 5,500 drug monographs; 128,000

preparations; 40,700 reference citations; 10,900 manufacturers. There are synopses of disease treatments which enables identification of medicines, the local equivalent and the manufacturer. It also Includes herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins, and poisons as well as drugs and medicines. Based on published information and extensively referenced

Intravenous Therapy in Nursing Practice provides a comprehensive guide to the management of intravenous therapy in nursing, and explores all aspects of intravenous therapy in both hospital and community settings. It addresses core clinical skills, including the preparation and administration of intravenous drugs, peripheral venous access, acute and long term central venous access, and paediatric intravenous therapy. The book also explores relevant anatomy and physiology, fluid and electrolyte balance, pharmacological aspects and legal and ethical issues, in order to equip nurses with the skills and knowledge needed in order to provide safe and effective care. • Addresses key specialist skills, including blood transfusion, parenteral nutrition and safe administration of cytotoxic drugs • A definitive text for nurses working in the hospital and the community • Contains contributions from leading nurse practitioners Intravenous Therapy in Nursing Practice is an essential resource for nurses and health professionals working in intravenous therapy.

British Pharmacopoeia 2005Stationery Office/Tso

Building on the success of the 14 previous editions, this remarkable reference has been extensively reorganized and expanded and now comprises almost 1,500 individual drug articles providing the most complete coverage of adverse reactions and interactions found anywhere. Each article contains detailed and authoritative information about the adverse effects of each drug, with comprehensive references to the primary literature making this a must have for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary or pharmaceutical company. Now available online for all academic, corporate or government institution as well as individuals via Science Direct! The online version provides an unparalleled depth of coverage and functionality by offering convenient desktop access and enhanced features such as increased searchability, extensive internal cross-linking and fully downloadable and printable full-text, HTML or PDF articles. Enhanced encyclopedic format with drug monographs now organised alphabetically Completely expanded coverage of each drug - thalidomide warranted three sentences in Meyler's 14th edition, but is now a 13 page extensive monograph Clearer, systematic organization of information for easier reading including case histories to provide perspective on each listing Extensive bibliography with over 40,000 references - Meyler's 15th edition incorporates all relevant citations from Meyler's 14th, but also includes relevant citations from previous editions of Meyler's and Side Effects of Drugs Annuals to give a historical perspective on the use and safety of drugs

Effective date: 1 December 2005. Supplement to the 2002 main ed. (ISBN 011322558X). Cover title of main edition: British approved names 2002 incorporating international nonproprietary names. A dictionary of drug names for regulatory use in the UK

This book details: 1. Development and validation of a HPTLC-densitometric method for concurrent estimation of metformin hydrochloride, pioglitazone hydrochloride and gliclazide in combined dosage form. 2. Development and validation of a HPTLC method for simultaneous estimation of moxifloxacin hydrochloride and dexamethasone sodium phosphate in combined pharmaceutical dosage form. 3. Development and validation of a RP-HPLC method for simultaneous estimation of ciprofloxacin hydrochloride and dexamethasone in combined dosage form, which is a better alternative to existing ones. The developed analytical methods are simple, selective, accurate, robust, and precise with shorter analysis time for the analysis of drug/s in combined pharmaceutical dosage forms. All the developed HPTLC and HPLC methods have been validated as per ICH Q2 (R1) guideline. Developed analytical methods could boost analytical researchers to work more efficiently in the field of analytical method development and validation of Pharmaceutical dosage forms.

This set comprises of five volumes and a CD-ROM: i) four volumes detailing all current UK pharmacopoeial standards for medicines for human use; ii) a companion volume providing standards for substances, preparations and immunological products used in veterinary medicine; and iii) a fully searchable CD-ROM which contains the contents of these volumes in electronic form together with a user manual, as well as the British Approved Names 2002 and supplements. The Pharmacopoeia is published on the recommendation of the Medicines Commission in accordance with the Medicines Act 1968. This edition is effective from 1 December 2005 and it incorporates the requirements of the 5th edition of the European Pharmacopoeia 2004 and its supplements.

Are herbal drugs totally devoid of adverse effects when used alone, as herbal formulations, or in concurrent use with modern medicines? Safety Concerns for Herbal Drugs examines that question and others like it to give you the information you need to judge for yourself the balance between the risks and benefits associated with the therapeutic use of medicinal plants. It stands out from other books by directing your attention to the aspects of safety and toxicity. The authors venture into the relatively unexplored (or deliberately hidden) side of the picture. They present a survey of approximately 1500 medicinal plants and herbal products, 59 global (from 27 countries) and 75 Indian examples of toxic and adverse effects and drug interactions. Additionally, they present the current status of regulatory laws and their enforcement in 73 countries to support their contention that such laws and enforcement are inadequate, and that herbal drugs are unscientifically being promoted as totally safe. To give you the full picture, the authors go on to examine such issues as danger from large-scale misuse and abuse, self-prescription, substitution, adulteration, concurrent use with modern medicines, hazardous but avoidable drug interactions, risk groups, and present status of drug regulations.